Skip to content
Search

Latest Stories

Fake Ozempic and Saxenda pens found in the UK

MHRA has seized the injections sold through ‘non-legitimate’ routes

The Medicines and Healthcare products Regulatory Agency (MHRA) has warned the public to avoid buying pre-filled weight loss pens without a prescription.


The warning came after 369 fake Ozempic injections have been seized since January 2023.

However, Saxenda pens were obtained by members of the public in the UK through "non-legitimate routes".

The health regulator has urged the public to buy the pens after consulting a healthcare professional and with a prescription.

Dr Alison Cave, MHRA Chief Safety Officer shared her opinion on the matter, she said: “Buying products such as Ozempic or Saxenda without a prescription, from illegally trading suppliers, significantly increases the risk of receiving something which is either fake or not licensed for use in the UK.

“Products purchased in this way do not meet our strict quality and safety standards, and taking such medicines may put your health at significant risk.

She added: “We are advising all members of the public not to use any pre-filled weight loss pens they may have bought online and instead to report it to us so that we can investigate and take any necessary action.”

saxenda Saxenda is used for weight loss with diet and exercise. Credit: iStock

Since, the active pharmaceutical ingredient (API) found in the pens, Semaglutide and Liraglutide are prescription-only medicines.

The Ozempic is authorised in the UK for the treatment of adults with type 2 diabetes, while Saxenda is used for weight loss with diet and exercise.

However, Ozempic is commonly used off-label for weight loss in the UK.

Health Minister Will Quince said: “No one should put profit before the needs of patients, but fraudsters selling black market medicines like this are extremely dangerous and can put people’s health at risk.

“The medical advice is clear: patients should only use medicines like Ozempic or Saxenda where they’ve been prescribed it by a legitimate source, such as their GP or another legitimate prescriber.

“The MHRA have our full support in cracking down on these illegal online suppliers to ensure that patients are protected.”

MHRA confirmed that Ozempic had been found at two UK wholesalers on 18 October.

Last week, several Austrians were taken to the hospital after injecting fake Ozempic but the number of hospitalisations in the UK is still unknown.

Austria’s Federal Office for Safety in Health Care (BASG) confirmed that the patients have suffered hypoglycaemia shock, coma, and seizures.

It is believed that the injections contained insulin instead of the weight loss drug, semaglutide.

The surge in the sale of fake Ozempic has been flagged by the drug’s Danish manufacturer, Novo Nordisk.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less